본문 바로가기
KERD
논문KCI 등재

Effect of Gongjindon a Traditional Korean Polyherbal Formula, on the Pharmacokinetics Profiles of Donepezil in Male SDRats (1) -Single Oral Combination Treatment of Donepezil 10mg/kg with Gongjindan 100mg/kg within 5 min -

이영준|박수진|구세광|정대규|권오대
대한예방한의학회 (Society of Preventive Korean Medicine)|2013.04|대한예방한의학회지 (Society of Preventive Korean Medicine)|제17권 제1호|pp. 77-88

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

PharmacokineticsDrug-drug interactionsRatGongjindanDonepezil
주제분류한의학

초록

Objectives : This study was aim to evaluate effects of pharmacodynamics and toxicity in combination therapy of donepezil with Gongjindan. Methods : After 10mg/kg of donepezil treatment, Gongjindan 100mg/kg was administered within 5 min. The plasma were collected at 30min before administration, 30min, 1, 2, 3, 4, 6, 8 and 24hrs after end of Gongjindan treatment, and plasma concentrations of donepezil were analyzed using LC-MS/MS methods. PK parameters of donepezil were analysis as compared with donepezil single administered rats. Results : Gongjindan markedly inhibited the absorption of donepezil regardless of sample time, from 30min to 8hrs after end of co-administration comparing with donepezil single treated rats. Especially the absorption of donepezil was significantly decreased at 2hrs after co-administration as compared with donepezil single treated rats, in the present study. Accordingly, the Cmax(-27.76%), AUC0-t(-27.22%) and AUC0-inf(-26.54%) of donepezil in co-administered rats were significantly decreased as compared with donepezil single treated rats, respectively. Conclusions : Based on the results of the present study, co-administration of Gongjindan decreases the oral bioavailability of donepezil by inhibiting the absorption. It is considered that the more detail pharmacokinetic studies should betested to conclude the effects of Gongjindan on the pharmacokinetics of donepezil, when they were co-administered, like the effects after co-administration with reasonable intervals considering the Tmax of donepezil and after repeated co-administrations

Abstract

Objectives : This study was aim to evaluate effects of pharmacodynamics and toxicity in combination therapy of donepezil with Gongjindan. Methods : After 10mg/kg of donepezil treatment, Gongjindan 100mg/kg was administered within 5 min. The plasma were collected at 30min before administration, 30min, 1, 2, 3, 4, 6, 8 and 24hrs after end of Gongjindan treatment, and plasma concentrations of donepezil were analyzed using LC-MS/MS methods. PK parameters of donepezil were analysis as compared with donepezil single administered rats. Results : Gongjindan markedly inhibited the absorption of donepezil regardless of sample time, from 30min to 8hrs after end of co-administration comparing with donepezil single treated rats. Especially the absorption of donepezil was significantly decreased at 2hrs after co-administration as compared with donepezil single treated rats, in the present study. Accordingly, the Cmax(-27.76%), AUC0-t(-27.22%) and AUC0-inf(-26.54%) of donepezil in co-administered rats were significantly decreased as compared with donepezil single treated rats, respectively. Conclusions : Based on the results of the present study, co-administration of Gongjindan decreases the oral bioavailability of donepezil by inhibiting the absorption. It is considered that the more detail pharmacokinetic studies should betested to conclude the effects of Gongjindan on the pharmacokinetics of donepezil, when they were co-administered, like the effects after co-administration with reasonable intervals considering the Tmax of donepezil and after repeated co-administrations

참고문헌 (38)

  1. Birks J, "Donepezil for dementia due to Alzheimer’s disease", Cochrane database of systematic reviews, (1), pp.CD001190~ (2006)
  2. Rogers SL, "Perspectives in the management of Alzheimer’s disease: clinical profile of donepezil", Dementia and geriatric cognitive disorders, 9(Suppl 3), pp.29~42 (1998)
  3. Roman GC, "Donepezil: a clinical review of current and emerging indications", Expert opinion on pharmacotherapy, 5(1), pp.161~180 (2004)
  4. Rojas-Fernandez CH, "Successful use of donepezil for the treatment of dementia with Lewy bodies", The Annals of pharmacotherapy, 35(2), pp.202~205 (2001)
  5. Malouf R, "Donepezil for vascular cognitive impairment", Cochrane database of systematic reviews, (1), pp.CD004395~ (2004)
  6. Moraes W, "Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study", Chest, 133(3), pp.677~683 (2008)
  7. Riedel G, "Scopolamine-induced deficits in social memory in mice: reversal by donepezil", Behavioural brain research, 204(1), pp.217~225 (2009)
  8. Handen BL, "Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures", Journal of child and adolescent psychopharmacology, 21(1), pp.43~50 (2011)
  9. PfizerCanada Inc.., "PRODUCT MONOGRAPH PrARICEPT® (donepezil hydrochloride) Tablets 5 and 10 mg PrARICEPT RDTTM (donepezil hydrochloride) Rapidly Disintegrating Tablets 5 and 10 mg Cholinesterase Inhibitor", FDA Submission Control No: 107207, ~ (2007)
  10. Dunn NR, "Adverse effects associated with the use of donepezil in general practice in England", Journal of psychopharmacology, 14(4), pp.406~408 (2000)
  11. Benazzi F., "Mania associated with donepezil", Journal of psychiatry & neuroscience, 24(5), pp.468~469 (1999)
  12. Umegaki H, "Discontinuation of donepezil for the treatment of Alzheimer’s disease in geriatric practice", International psychogeriatrics, 20(4), pp.800~806 (2008)
  13. Lockhart IA, "Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer’s disease: systematic review of the ‘real-world’ evidence", Dementia and geriatric cognitive disorders, 28(5), pp.389~403 (2009)
  14. Tiseo PJ, "Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses", British journal of clinical pharmacology, 46(Suppl 1), pp.25~29 (1998)
  15. Tiseo PJ, "Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses", British journal of clinical pharmacology, 46(Suppl 1), pp.30~34 (1998)
  16. Yasui-Furukori N, "The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil", Journal of clinical pharmacology, 44(5), pp.538~542 (2004)
  17. Tiseo PJ, "Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes", British journal of clinical pharmacology, 46(Suppl 1), pp.40~44 (1998)
  18. Tiseo PJ, "Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers", British journal of clinical pharmacology, 46(Suppl 1), pp.35~39 (1998)
  19. Tiseo PJ, "The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin", British journal of clinical pharmacology, 46(Suppl 1), pp.45~50 (1998)
  20. Kim YH, "The effect of Kong Jin Dan on the lipid metabolism in rats fed high fat-diet", J East-West Med, 14, pp.61~78 (2001)
  21. Kim YS, "The Effect of Gongjindan Aqua-acupuncture on the CD4+ T cell count at al. in rats were administered with MTX", J Korean Acup Moxi Soc, 16, pp.179~202 (1999)
  22. 박치상, "拱辰丹의 성분 분석 및 抗酸化 작용에 미치는 영향", 대한본초학회지, 22(2), pp.51~63 (2007), 대한본초학회
  23. 성기문, "공진단이 MCAO모델 흰쥐에서 gliosis 억제에 미치는 영향", 대한한방내과학회지, 30(4), pp.674~684 (2009), 대한한방내과학회
  24. 황선미, "공진단이 CT105로 유도된 Alzheimer's disease 병태모델에 미치는 영향", 동의신경정신과학회지, 15(2), pp.103~118 (2004), 대한한방신경정신과학회
  25. 정효창, "공진단이 알츠하이머형 치매 환자에게 미치는 영향", 동의신경정신과학회지, 15(2), pp.141~148 (2004), 대한한방신경정신과학회
  26. 구세광, "Single Oral Dose Toxicity Test of Kong-Jin-Dan, a Polyherbal Formula in ICR Mice", 응용약물학회지, 15(4), pp.245~251 (2007), 한국응용약물학회
  27. Sang-Nam Lee, "Micronucleus Test of Kong-Jin-Dan, a Polyherbal Formula, in Bone Marrow Cells of Male ICR Mice", 한국독성학회지, 24(3), pp.213~218 (2008), 한국독성학회
  28. Gibaldi M, "Pharmacokinetics" (1982), Marcel-Dekker
  29. Bailer AJ, "Testing for the equality of area under the curves when using destructive measurement techniques", Journal of pharmacokinetics and biopharmaceutics, 16(3), pp.303~309 (1988)
  30. Chiou WL, "Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve", Journal of pharmacokinetics and biopharmaceutics, 6(6), pp.539~546 (1978)
  31. UHC drug monograph: Donepezil, "Dickinson BD", UHC (University Health System Consortium) Services Corporation, 1~14 (1996)
  32. Mihara M, "Pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy male volunteers", International journal of clinical pharmacology, therapy, and toxicology, 31(5), pp.223~229 (1993)
  33. Tiseo PJ, "Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration", British journal of clinical pharmacology, 46(Suppl 1), pp.13~18 (1998)
  34. Tiseo PJ, "Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study", British journal of clinical pharmacology, 46(Suppl 1), pp.19~24 (1998)
  35. Rogers SL, "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group", Neurology, 50(1), pp.136~145 (1998)
  36. Rogers SL, "Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study", European neuropsychopharmacology, 8(1), pp.67~75 (1998)
  37. Matsui K, "Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat", Drug metabolism and disposition: the biological fate of chemicals, 27(12), pp.1406~1414 (1999)
  38. Tiseo PJ, "An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function", British journal of clinical pharmacology, 46(Suppl 1), pp.51~55 (1998)

관련 논문AI추천

Effect of Gongjindan, a Traditional Korean Polyherbal Formula, on the Pharmacokinetics Profiles of Donepezil in Male SDRats (2) ― Single Oral Combination Treatment of Donepezil 10mg/kg with Gongjindan 100mg/kg, 1.5hr-intervals with 7-day Repeated Treatment ―구세광, 권오대, 박수진, 이영준, 정대규대한예방한의학회 · 대한예방한의학회지2013 · 제17권 제2호Effect of Gongjindan, a Polyherbal Formula on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (1) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan 100mg/kg within 5min -강수진, 구세광, 김승모, 박수진, 송창현, 이영준, 이창형, 한창현대한예방한의학회 · 대한예방한의학회지2014 · 제18권 제2호Effect of Gongjindan-gamibang on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (2) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan-gamibang 100 mg/kg, 3.5hr-intervals with 7-day Repeated Treatment -강수진, 구세광, 김승모, 박수진, 송창현, 이영준, 이창형, 한창현대한예방한의학회 · 대한예방한의학회지2015 · 제19권 제1호Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Single Oral Combination Treatment of Tamoxifen 50 mg/kg with GMODT 100 mg/kg with 2.5 hr-intervals -강수진, 구세광, 류은아, 송창현, 이봉효, 이영준, 최성훈, 한창현대한예방한의학회 · 대한예방한의학회지2017 · 제21권 제2호Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated Co-administration곽민아, 구세광, 박성환, 박수진, 이영준대한예방한의학회 · 대한예방한의학회지2016 · 제20권 제2호생약제제의 약물동태 연구 및 상호작용강원구, 김은정, 노금한, 윤영란, 이혜원, 임미선, 정원필한국임상약학회 · 한국임상약학회지2010 · 제20권 제2호

이 간행물의 다른 논문 (14건)

본초 상호작용 관계망 분석 및 활용 방향이정현, 권오민pp. 1-11일부 여고생의 스트레스와 스트레스 대처방식 및 신체증상 영향요인김영희, 양경희, 박금숙pp. 13-25웰빙 개념에 대한 국내 연구 현황 분석한창현, 이영준, 이상남, 박황진pp. 27-50네이버 지식인을 통해 본 한의학 인터넷 건강 상담의 현황김윤경, 임병묵pp. 51-6312개 미래 예측 한의약 정책 과제의 실현 평가 연구박주영, 신현규pp. 65-76
원문 보기